首页> 美国卫生研究院文献>other >Quality Control of the Traditional Patent Medicine Yimu Wan Based on SMRT Sequencing and DNA Barcoding
【2h】

Quality Control of the Traditional Patent Medicine Yimu Wan Based on SMRT Sequencing and DNA Barcoding

机译:基于SMRT测序和DNA条形码的中成药万物的质量控制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Substandard traditional patent medicines may lead to global safety-related issues. Protecting consumers from the health risks associated with the integrity and authenticity of herbal preparations is of great concern. Of particular concern is quality control for traditional patent medicines. Here, we establish an effective approach for verifying the biological composition of traditional patent medicines based on single-molecule real-time (SMRT) sequencing and DNA barcoding. Yimu Wan (YMW), a classical herbal prescription recorded in the Chinese Pharmacopoeia, was chosen to test the method. Two reference YMW samples were used to establish a standard method for analysis, which was then applied to three different batches of commercial YMW samples. A total of 3703 and 4810 circular-consensus sequencing (CCS) reads from two reference and three commercial YMW samples were mapped to the ITS2 and psbA-trnH regions, respectively. Moreover, comparison of intraspecific genetic distances based on SMRT sequencing data with reference data from Sanger sequencing revealed an ITS2 and psbA-trnH intergenic spacer that exhibited high intraspecific divergence, with the sites of variation showing significant differences within species. Using the CCS strategy for SMRT sequencing analysis was adequate to guarantee the accuracy of identification. This study demonstrates the application of SMRT sequencing to detect the biological ingredients of herbal preparations. SMRT sequencing provides an affordable way to monitor the legality and safety of traditional patent medicines.
机译:不合格的传统专利药可能会导致全球安全相关的问题。保护消费者免受与草药制剂的完整性和真实性相关的健康风险的关注。特别需要关注的是传统专利药品的质量控制。在这里,我们建立了一种基于单分子实时(SMRT)测序和DNA条形码验证传统专利药品生物成分的有效方法。选择了《中国药典》中记载的经典草药处方“一木万”(YMW)来测试该方法。使用两个参考YMW样品建立分析的标准方法,然后将其应用于三个不同批次的商业YMW样品。从两个参考样本和三个商业YMW样本中总共读取了3703个和4810个圆形共识测序​​(CCS)读数,分别映射到ITS2和psbA-trnH区。此外,基于SMRT测序数据的种内遗传距离与来自Sanger测序的参考数据的比较发现,ITS2和psbA-trnH基因间隔子表现出很高的种内差异,变异位点在物种内部显示出显着差异。使用CCS策略进行SMRT测序分析足以保证鉴定的准确性。这项研究证明了SMRT测序在检测草药制剂的生物成分中的应用。 SMRT测序为监测传统专利药物的合法性和安全性提供了一种负担得起的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号